secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001558370-23-014916
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Q2 net loss $2.3M; cash drops to $1.2M; PMN310 IND cleared
-----------------------------------------------------------------

- Net loss $2.3M vs $2.7M YoY; R&D expense fell to $1.0M from $3.2M.
- Cash and equivalents $1.2M at June 30, 2023, down from $5.9M at Dec 31, 2022.
- PMN310 received FDA IND clearance in May 2023; Phase 1a planned subject to capital.
- Preclinical data at AAIC 2023 showed PMN310 selectively targets toxic amyloid beta oligomers with potential for improved safety.
- Shares delisted from TSX in July 2023; now trades solely on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837023014916/0001558370-23-014916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837023014916/pmn-20230814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer